pLKO-shBRCA1 #1 Citations (3)

Originally described in: A two-step mechanism for TRF2-mediated chromosome-end protection.
Okamoto K, Bartocci C, Ouzounov I, Diedrich JK, Yates Iii JR, Denchi EL Nature. 2013 Feb 6. doi: 10.1038/nature11873. PubMed Journal

---

Articles Citing pLKO-shBRCA1 #1

Articles
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy. Lei JH, Lee MH, Miao K, Huang Z, Yao Z, Zhang A, Xu J, Zhao M, Huang Z, Zhang X, Chen S, Jiaying NG, Feng Y, Xing F, Chen P, Sun H, Chen Q, Xiang T, Chen L, Xu X, Deng CX. Adv Sci (Weinh). 2021 Nov;8(21):e2100974. doi: 10.1002/advs.202100974. Epub 2021 Sep 13. PubMed
S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, Liu J, Zhang X, Adhav R, Chen Q, Wang Y, An T, Zhang X, Lyu X, Li X, Lei JH, Miao K, Sun H, Xing F, Zhang A, Deng C, Xu X. Nat Commun. 2022 Mar 18;13(1):1481. doi: 10.1038/s41467-022-29151-5. PubMed
Senescence plays a role in myotonic dystrophy type 1. Garcia-Puga M, Saenz-Antonanzas A, Gerenu G, Arrieta-Legorburu A, Fernandez-Torron R, Zulaica M, Saenz A, Elizazu J, Nogales-Gadea G, Gadalla SM, Arauzo-Bravo MJ, Lopez de Munain A, Matheu A. JCI Insight. 2022 Oct 10;7(19):e159357. doi: 10.1172/jci.insight.159357. PubMed

If you have published an article using this material, please email us at to have your article added to this page.